News
Patients treated with Bristol Myers Squibbās Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy.
FEATURED STORIES
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously āundruggableā cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. Itās a start, but new agency leadership must see it through.
Significant leadership instability at the FDAācompounded by continued workforce attritionāled to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has been catching up of late.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmasā clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian countryās biotech industry.
THE LATEST
The draft guidance supports the agencyās new pathway designed to speed up the development of custom gene therapies.
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology research at its South San Francisco, California, and Westborough, Massachusetts, sites.
In this bonus episode, BioSpaceās Vice President of Marketing ā Chantal Dresnerā and Careers Editor ā Angela Gabrielā take a look at Q1 job market performance and what it signals for the coming months.
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is āoff to a fast start in 2026,ā CEO Joaquin Duato told investors on Tuesday.
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
Eli Lilly is putting its obesity windfall to work again, striking a new deal to acquire CrossBridge Bio, a small Texas biotech known for its cancer tech.
During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral GLP-1 medicine, while other companies are expected to address the FDA, drug pricing and Trumpās new tariffs.
The FDA has greenlit Travere Therapeuticsā Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drugās loss to Sanofiās Avapro in a Phase 3 study.
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the federal governmentās public repository for studies, according to internal data from the FDA.
Bringing patients into the drug development process early has proven to save time, money and resources.